Aquestive Therapeutics (AQST)
US Market

Aquestive Therapeutics (AQST) Stock Price & Analysis


AQST Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.72 - $2.69
Previous Close$1.53
Average Volume (3M)322.20K
Market Cap
Enterprise Value$124.78M
Total Cash (Recent Filing)$22.44M
Total Debt (Recent Filing)$45.12M
Price to Earnings (P/E)-3.4
Nov 07, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding61,726,668
10 Day Avg. Volume285,875
30 Day Avg. Volume322,203
Standard Deviation0.33
Financial Highlights & Ratios
Price to Book (P/B)-0.86
Price to Sales (P/S)7.13
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.68
Enterprise Value/Gross Profit2.62
Enterprise Value/Ebitda-8.71
Price Target Upside270.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3



Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $0.72 and its highest was $2.69 in the past 12 months.
    What is Aquestive Therapeutics’s market cap?
    Currently, no data Available
    When is Aquestive Therapeutics’s upcoming earnings report date?
    Aquestive Therapeutics’s upcoming earnings report date is Nov 07, 2023 which is in 37 days.
      How were Aquestive Therapeutics’s earnings last quarter?
      Aquestive Therapeutics released its earnings results on Aug 07, 2023. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.117 by $0.017.
        Is Aquestive Therapeutics overvalued?
        According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Aquestive Therapeutics pay dividends?
          Aquestive Therapeutics does not currently pay dividends.
          What is Aquestive Therapeutics’s EPS estimate?
          Aquestive Therapeutics’s EPS estimate is -$0.11.
            How many shares outstanding does Aquestive Therapeutics have?
            Aquestive Therapeutics has 66,727,295 shares outstanding.
              What happened to Aquestive Therapeutics’s price movement after its last earnings report?
              Aquestive Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.117. Following the earnings report the stock price went down -5.366%.
                Which hedge fund is a major shareholder of Aquestive Therapeutics?
                Among the largest hedge funds holding Aquestive Therapeutics’s share is Caxton Associates LP. It holds Aquestive Therapeutics’s shares valued at N/A.


                  Aquestive Therapeutics Stock Smart Score

                  The Aquestive Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  Aquestive Therapeutics

                  Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.


                  Top 5 ETFs holding AQST

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Up to five ETFs with an Outperform Smart Score that hold AQST. The ETFs are listed according to market value of AQST within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  Atossa Therapeutics
                  Cyclacel Pharmaceuticals
                  Corvus Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis